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 Background 
 Psoriasis is a frequent chronic infl ammatory disease 
that primarily aff ects the skin. Currently incurable pso-
riasis can occur at any age, is equally distributed between 
men and women, and has a higher prevalence in Cauca-
sians compared to African-Americans  [1, 2] . Clinically, 
the severity of psoriasis is described by the intensity and 
extent of the psoriatic lesions. From the patients’ perspec-
tive, however, the impact psoriasis has on their everyday 
physical, social and psychological-emotional functioning 
is most important  [3–6] . 
 Th e introduction of biological agents in the treatment 
of psoriasis off ers patients new hope for safe and eff ective 
therapy  [7–11] . Comparatively high acquisition costs of 
these new agents however evoked a debate about their ap-
propriate use  [12] . Th is is one reason why pharmacoeco-
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 Abstract 
 Background: According to current guidelines the cost of 
productivity loss should be considered in pharmacoeco-
nomic analyses. The cost of health-related productivity loss 
in psoriasis patients is unknown.  Objective: To estimate the 
cost of productivity loss in psoriasis and its association with 
health-related quality of life and clinical disease severity. 
 Methods: Cross-sectional study, recruitment of adult partic-
ipants through Internet advertisements. 201 (72.3%) out of 
278 eligible participants completed the study. Health-relat-
ed work productivity loss, quality of life and clinical severity 
of psoriasis were assessed by standardized instruments.  Re-
sults: Indirect costs of productivity loss clearly exceed the 
total direct cost. In contrast to objective clinical disease se-
verity, health-related quality of life (measured by the Derma-
tology Life Quality Index) is an independent predictor of 
work productivity.  Conclusions: There is good reason to be-
lieve that intervention can reduce health-related productiv-
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nomic analyses have recently gained more interest in the 
dermatological literature  [13–18] . Guidelines for phar-
macoeconomic studies recommend to use the societal 
perspective, which means that direct and indirect costs of 
disease need to be considered  [19–22] . Th e direct costs are 
the cost for the intervention itself, e.g. drugs, physician 
visits and hospitalization cost. Related direct costs include 
expenditures on information material and transportation 
cost. In a recent study the annual direct cost of psoriasis 
treatment in the USA has been estimated to be about 650 
million USD, more than half of which is spent on over-
the-counter drugs  [16] . Indirect costs are defi ned as op-
portunity cost of persons unable to work. Th ese costs due 
to lost productivity include costs of absenteeism and pre-
senteeism  [23, 24] . ‘Presenteeism’ is defi ned as lost pro-
ductivity because of illness or other medical conditions 
while on the job  [25, 26] . With estimated total costs of 150 
billion USD per year in the USA, the total costs of presen-
teeism exceed those of absenteeism  [25] . Although it is 
crucial to include the costs resulting from productivity 
loss in pharmacoeconomic evaluations, corresponding 
data for psoriasis patients have not been assessed yet.  
 Our aim was to estimate the cost of work productivity 
loss in patients with psoriasis. We were further interested 
in the association of productivity loss, health-related qual-
ity of life (HRQL) and clinical disease severity. 
 Methods 
 Setting and Study Population 
 Th e presented data were collected in the context of a larger 
cross-sectional study on the morbidity of psoriasis patients, which 
was conducted through the Internet between January and May 
2005. Patients 18 years or older with self-reported psoriasis who 
accessed the Internet from the USA were eligible. Th e geographical 
identifi cation of Internet users was inferred from the correspond-
ing Internet protocol addresses. Recruitment included an adver-
tisement at google.com that appeared on the screen when ‘psoria-
sis’ or related search terms were entered. Th e advertisement was 
‘Johns Hopkins Study. Psoriasis & Quality of Life – 30-min ques-
tionnaire – get your report back’. Aft er clicking the web-link of the 
advertisement, participants entered the interactive study Internet 
page. 
 Ethical approval from the Offi  ce for Research Subjects, Johns 
Hopkins Bloomberg School of Public Health, Baltimore, Md., was 
received prior to initiating the study. All participants provided 
 informed consent before starting to answer the study question-
naires. 
 Assessments 
 Presenteeism , defi ned as lost productivity while on the job, was 
assessed using the output demands component of the Work Limi-
tations Questionnaire (WLQ)  [27] . Th e WLQ is a self-report in-
strument with adequate psychometric properties (internal consis-
tency, construct validity, reliability, accuracy)  [26] . It measures the 
on-the-job impact of chronic conditions within the past 2 weeks 
and has already been applied in various psychiatric and rheumato-
logical conditions  [26, 28–31] . From the four WLQ domains (time, 
physical, output and mental-interpersonal demands) the output de-
mands domain has the highest relative validity and has been shown 
to be the best predictor of productivity loss. Th e other WLQ scales 
each exhibit only half the predictive power of the output demands 
scale or less  [27] . Th e output demands scale includes 5 items (han-
dling the workload, fi nishing work on time, working fast enough, 
working without making mistakes, doing what one is capable of do-
ing). Items are scored on a 0% (limited none of the time) to 100% 
(limited all of the time) scale. Th e total output demands score is the 
average item score. It indicates the percentage of time in the prior 2 
weeks the respondent was limited performing output demands 
 [27] . 
 An advantage of the WLQ is that it has been validated against 
actual work productivity loss: for every 10% increase in the WLQ 
output demands scale, actual work productivity declined by ap-
proximately 4.5%  [32] . Th is allowed us to approximate the eco-
nomic impact of presenteeism due to psoriasis in the USA in terms 
of USD by applying the following formula: 
mean total output demands score    0.45%    annual average
income    prevalence    [US population age 18–65    
(1 – unemployment rate)]
 with: 
 • average annual income (2002): USD 36,764  [33] 
 • prevalence: 2.5% in Caucasians, 1.3% in African-Americans 
 [2]; ] weighted average  [34] = 2.5    86% + 1.3    14% = 2.3% 
 • US population aged 18–65  [34] : 174,243,050 
 • unemployment rate (our data used, see below): 16.3% 
 Th e assumptions made for this estimation are discussed be-
low. 
 To assess the time lost from work because of  absences, partici-
pants were asked to indicate how many workdays they had missed 
fully and partly within the past 4 weeks due to health or medical 
care and how many workdays they missed due to other reasons. A 
full workday missed was given the value of 1, a part day one of 0.5 
 [30] . Th e monetary economic impact of health-related absenteeism 
of persons with psoriasis in the USA was estimated by: 
 percent workdays missed due to medical reasons    
average annual income    prevalence    
[US population age 18–65    (1 – unemployment rate)]. 
 We added the cost of presenteeism and the cost of absenteeism 
to estimate the  total cost of health-related work productivity loss 
(HRWPL) in patients with psoriasis in the USA. 
 HRQL  was assessed using the Dermatology Life Quality Index 
(DLQI), a widely used instrument with adequate psychometric 
properties (e.g. validity, reliability, sensitivity to change)  [35–37] . It 
consists of 10 questions considering the following domains: symp-
toms and feelings, daily activities, leisure, work and school, per-
sonal relationships, and the eff ects of treatment on daily life. 
 Th e self-administered Psoriasis Area and Severity Index
(SAPASI) is a patient-rated instrument with adequate psycho-
metric properties to assess the  objective clinical severity of psoria-
sis  [38–42] . To be applicable in the Internet setting, the SAPASI
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was slightly modifi ed (mSAPASI): as in the original version, pa-
tients rated the intensity of erythema, induration and scaliness on 
a 12-cm visual analogue scale (VAS)  [40] . For estimation of the in-
volved body surface area (BSA), patients were informed that the 
area of their palmar hand equals roughly 1% of their BSA. Partici-
pants were then asked to estimate the percentage of their body cov-
ered with psoriatic plaques. As in the original PASI, the percent 
BSA involvement was recategorized into a semiquantitative score 
with 0 indicating no, 1 = 1–9%, 2 = 10–29%, 3 = 30–49%, 4 = 50–
69%, 5 = 70–89% and 6 = 90–100% BSA involvement  [43] . 
 Th e mSAPASI was calculated using the formula: 
 [(VAS erythema + VAS scaliness + VAS induration)/3]    
BSA score. 
 Th e mSAPASI score ranges from 0 to 72 with higher scores in-
dicating higher objective disease severity. Severe psoriasis was de-
fi ned as mSAPASI  1 12, a score between 7 and 12 as moderate pso-
riasis, and a score of less than 7 as mild psoriasis  [44] . 
 Information on sociodemographic characteristics included age, 
sex, ethnicity, annual household income, education level and aver-
age weekly worktime. Information on specifi c disease characteris-
tics of psoriasis included diagnosis by physician, treatment within 
the past 14 days, joint involvement and presence/absence of facial 
lesions, genital lesions, hand involvement and feet involvement 
within the past 14 days. Participants were also asked to rate their 
overall health state on a 5-point Likert scale and to indicate if they 
were temporarily or permanently disabled.  
 To increase internal validity, participants were also asked to in-
dicate whether they answered all questions honestly and whether 
they had completed the study questionnaire more than once. Par-
ticipants indicating they did not answer honestly or were partici-
pating more than once were excluded from the analysis. Th e ques-
tionnaire was designed in a way that allowed proceeding to the next 
set of questions only if all previous questions had been answered. 
Th erefore there were no missing data for our analysis. 
 Statistical Analysis 
 Th e    2  test and Fisher’s exact test were used to compare sociode-
mographic characteristics, disease characteristics and comorbidity 
of study participants by HRWPL (median defi ned as cutoff )  [45] . 
Spearman correlation coeffi  cients were calculated to describe the 
univariate association of HRWPL, DLQI and mSAPASI. Addition-
ally, univariate and multivariate logistic regression analyses were 
performed to describe factors associated with HRWPL. Th e fi t of 
the fi nal multivariate model was assessed by Hosmer-Lemeshow’s 
   2  test  [45] . 
 Th e study web page was programmed in PERL 5. Javascript was 
used for real-time data analysis. Th e data were recorded in an SQL 
database and transferred to Stata statistical soft ware 8.0 for Win-
dows, which was then used to perform the statistical analysis 
 [46] . 
 Results 
 A total of 332 persons between the age of 18 and 65 
started answering the questionnaires, 54 (16.3%) of whom 
were currently unemployed. From the remaining 278 par-
ticipants, 77 (27.7%) dropped out before answering the 
WLQ. Th e following results are based on the 201 partici-
pants who completed the study.  
 Th e sample was in the majority female, predominately 
white, less than 50% had completed a college education 
and about 78% worked full-time. Almost all participants 
(96%) had physician-diagnosed psoriasis, which was 
treated only topically in 59%, systemically in about 19% 
and not at all in 22% of the study subjects. Th e mean clin-
ical severity in terms of mSAPASI was 9.5 ( 8 8.9) with 
about half of the patients being categorized as having mild 
and about 25% as having moderate or severe psoriasis. 
About 22% of patients reported presence of psoriatic ar-
thritis, 48% lesions on their hands and 32% involvement 
of their face. Th e mean DLQI was 10.8 ( 8 7.1); three quar-
ters of the participants rated their health status as good, 
very good or excellent ( table 1 ). 
 Presenteeism and Absenteeism 
 On average, participants had missed 6.6% ( 8 15.4%) 
of their working time within the past 4 weeks because of 
health problems. Absences due to reasons other than 
health accounted for 7.3% ( 8 16.1%) of the working time. 
34% of participants had missed at least 1 day of work, and 
10% had missed 3 or more days of work within the past 4 
weeks due to problems with their health. Assuming gen-
eralizability of these results, the annual cost of health-re-
lated absenteeism of psoriasis patients in the USA amounts 
to about USD 7,696,308,000. Th e mean WLQ output de-
mands score was 16.8 ( 8 20.1) refl ecting a mean produc-
tivity loss because of presenteeism of 7.6% ( 8 9.1%), and 
an annual cost of about USD 8,862,415,000. Based on 
these numbers, the total HRWPL in psoriasis patients was 
calculated to amount to about USD 16,558,723,000.  
 Factors Associated with HRWPL 
 None of the sociodemographic characteristics assessed 
was signifi cantly associated with HRWPL. Patients with 
physician-diagnosed psoriasis tended to have a higher 
HRWPL (p = 0.07). Among patients with a higher
HRWPL, 57% reported lesions on their hands com-
pared to 39.6% of the subgroup with a lower HRWPL
(p = 0.01). Mild objective disease severity was associated 
with a lower likelihood of high HRWPL, whereas similar 
proportions were classifi ed as having severe psoriasis in 
the high- and low-HRWPL groups (26 vs. 23.8%;  table 1 ). 
Th e correlation between mSAPASI and HRWPL was only 
weak (  = 0.22). Both psoriatic arthritis and disability 
were more frequent in the subgroup with a higher HRW-
PL, but these associations were not statistically signifi cant. 
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Table 1. Comparison of sociodemographic characteristics, disease characteristics and comorbidity of study par-
ticipants by productivity loss because of disease-related absences and presenteeism (productivity loss 67.3% vs. 
<7.3%; n = 201)
Variable Total
(n = 201)
Productivity
loss 67.3%
(n =100)
Productivity 
loss <7.3%
(n = 101)
2 p value
Sociodemographics
Gender, % females 61.2 64.0 58.4 0.66 0.42
Mean age, years 42.7811.5
18–25 8.5 10.0 6.9
4.97 0.29
26–35 20.9 22.0 19.8
36–45 24.9 28.0 21.8
46–55 31.8 31.0 32.7
56–65 13.9 9.0 18.8
Race, % white 92.0 93.0 91.1 0.25 0.62
Annual household income
Less than 30,000 USD 18.9 19.0 18.8
30,000–60,000 USD 37.8 37.0 38.6 0.06 0.97
More than 60,000 USD 43.3 44.0 42.6
Educational level
No degree 6.5 6.0 6.9
0.07 0.97Highschool 46.8 47.0 46.5
College 46.8 47.0 46.5
Weekly worktime
0.14 0.71   !  35 h 21.9 23.0 20.8
635 h 78.1 77.0 79.2
Characteristics of psoriasis
Diagnosis by physician 96.0 99.0 93.1 – 0.07
Treatment within the past 14 days
None 21.9 18.0 25.7
Topical treatment 58.7 58.0 59.4 3.57 0.17
Systemic/UV treatment 19.4 24.0 14.9
Mean clinical severity (mSAPASI) 9.588.9
Mild (mSAPASI <7) 50.2 41.0 59.4
Moderate (mSAPASI 7–12) 24.9 33.0 16.8 8.77 0.01
Severe (mSAPASI >12) 24.9 26.0 23.8
Mean subjective severity (DLQI) 10.887.1
Low HRQL impairment (DLQI <6) 27.4 13.0 41.6
Moderate HRQL impairment (DLQI 6–12) 38.3 39.0 37.6 25.86 <0.01
Severe HRQL impairment (DLQI >12) 34.3 48.0 20.8
Psoriatic arthritis 21.9 26.0 17.8 1.97 0.16
Psoriatic lesions at special locations (current)
Face 32.3 35.0 39.7 0.64 0.42
Hands 48.3 57.0 39.6 6.09 0.01
Feet 38.3 44.0 32.7 2.73 0.10
Genital 41.8 47.0 36.6 2.22 0.14
Comorbidity
Overall health state, including psoriasis
Poor 3.0 5.0 1.0 – <0.01Fair 22.9 31.0 14.9
Good, very good, excellent 74.1 64.0 84.2
Temporal/permanent disability 4.5 7.0 2.0 – 0.10
Apart from mean age, mean clinical severity and mean subjective severity, results are expressed as percent-
ages. SD = Standard deviation; – = not applicable, Fisher’s exact test performed. 
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Self-classifi cation of the health status as ‘poor’ or ‘fair’ was 
a positive predictor for a higher HRWPL (p  ! 0.01;  ta-
ble 1 ). 
 A clear dose-response relationship between HRWPL 
and HRQL impairment was observed (p values for trend 
 ! 0.001 for all strata). More than 50% of the participants 
in the highest HRWPL tertile had a DLQI of more
than 12, whereas more than half of the patients with an 
HRWPL of less than 2% were also in the lowest DLQI 
group ( table 1 ,  fi g. 1 ). Th e correlation between DLQI and 
HRWPL was also highly statistically signifi cant (p  ! 0.001; 
  = 0.47). 
 Table 2 summarizes results from the univariate logis-
tic regression analysis. Compared to the subgroup with 
low HRQL impairment the odds of a higher HRWPL was 
3.32 for patients with moderate and 7.38 for patients with 
high HRQL impairment (p  ! 0.01 for each). Additional 
statistically signifi cant predictors for a high HRWPL in-
cluded moderate or severe objective disease severity 
(odds ratio = 2.11; p = 0.01) and psoriatic lesions on the 
hands (odds ratio = 2.02; p = 0.01;  table 2 ). In the fi nal 
multi-adjusted logistic regression model predicting 
HRWPL, only HRQL impairment (DLQI) and temporal/
permanent disability were independently associated 
with HRWPL ( table 3 ). Age, gender and annual house-
hold income, weekly working time, objective disease se-
verity (mSAPASI) and hand involvement were included 
in the fi nal model due to results from the univariate anal-
ysis and considerations regarding potential confound-
ing. Th e adjusted odds ratio of high HRWPL for partici-
pants with a DLQI score of 12 or more compared to those 
with a lower HRQL impairment (DLQI  ! 6) was 7.81
(p  ! 0.01;  table 3 ).  
 Fig. 1. Health-related productivity loss for participants by HRQL 
impairment (n = 201). p value for trend  ! 0.001. 
Covariate Odds 
ratio
95% confi dence 
interval
p value
Clinical severity (mild: mSAPASI <7) 
Moderate to severe: (mSAPASI 67) 2.11 1.20–3.70 0.009
Subjective severity (low: DLQI <6)
Moderate HRQL impairment (DLQI 6–12) 3.32 1.54–7.13 0.002
Severe HRQL impairment (DLQI >12) 7.38 3.30–16.54 <0.001
Psoriatic lesions at special locations (absent)
Face 1.27 0.70–2.30 0.423
Hands 2.02 1.15–3.55 0.014
Feet 1.62 0.91–2.87 0.100
Genital 1.53 0.87–2.69 0.137
Treatment within the past 14 days (none)
Topical treatment 1.39 0.69–2.82 0.351
Systemic/UV treatment 2.31 0.96–5.58 0.063
Overall health state (good, very good, excellent)
Fair 2.74 1.37–5.51 0.004
Poor 6.64 0.76–58.23 0.087
Temporal/permanent disability (absent) 3.73 0.75–18.39 0.106
Reference groups are indicated in parentheses.
Table 2. Univariate logistic regression
on productivity loss because of disease-
related absences and presenteeism 
(productivity loss 67.3% vs. productivity 
loss <7.3%; n = 201)
 Productivity Loss of Patients with 
Psoriasis 
Dermatology 2006;213:102–110 107
 Discussion 
 Not unexpectedly, we found evidence of substantial 
work productivity loss in patients with psoriasis. Indirect 
costs due to decreased productivity while on the job and 
due to health-related absenteeism seem to substantially 
exceed the direct cost of psoriasis treatment  [16] . 
 Th ere is good reason to believe that intervention can 
reduce HRWPL primarily by improving the patients’ 
HRQL. Positive impact on HRQL has recently been re-
ported for infl iximab, etanercept, alefacept, efalizumab 
and cyclosporine  [47–52] . Work productivity has not 
been included as an outcome in psoriasis studies yet. In 
patients with rheumatoid arthritis, Yelin et al. [53] found 
evidence of improved work productivity and employment 
status aft er etanercept treatment. Contrary to current 
guidelines on pharmacoeconomic analyses, published 
cost-eff ectiveness studies on antipsoriatic agents do not 
consider indirect cost and can therefore only draw an in-
complete picture of effi  ciency  [19–22, 54–57] . Th erefore, 
it is critically important to consider HRWPL in future ef-
fectiveness and cost-eff ectiveness studies on antipsoriatic 
remedies. It is possible that savings from increased work 
productivity off set the comparatively high acquisition 
costs of biologicals. Evidence for a high effi  ciency of these 
agents would fundamentally infl uence the ongoing debate 
about their appropriate indication and target population. 
 An advantage of collecting data over the Internet is that 
participants are more likely to disclose private issues, 
which may result in data with higher validity compared to 
other methodologies  [58, 59] . In an Internet-recruited 
sample patients from all diff erent geographical regions 
within the USA could easily participate. For both the In-
ternet setting and the US healthcare system, signifi cant 
ethnic and socioeconomic disparities regarding access ex-
ist  [60–62] . 
 As in other Internet-based studies, females and youn-
ger age groups appeared to be more likely and ethnic mi-
norities less likely to participate  [63] . Additionally, pa-
tients with psoriatic arthritis seem to be overrepresented 
in our sample. Here, misclassifi cation by considering ar-
throsis or other joint diseases unrelated to psoriasis as 
psoriatic arthritis might be present. It cannot be excluded 
that patients who are more frustrated with their psoriasis 
and who have experienced more disease-related adverse 
working eff ects than the average psoriasis patient were 
more likely to take the time to respond to the advertise-
ment and to complete the questionnaire so that recruit-
ment bias cannot be excluded. Th is type of selection bias 
might have led to an overestimation of adverse working 
eff ects in patients suff ering from psoriasis. Although re-
cruitment bias is a general problem associated with sur-
veys rather than a specifi c disadvantage of an Internet-
based study, our results should be interpreted with cau-
tion. To overcome the problem of selection bias in future 
studies on HRWPL in psoriasis we recommend to draw a 
suffi  ciently large random sample from a source popula-
tion in a clinical setting. In a survey on disease experi-
ences, it is possible that participants tend to recall health-
related problems better than experiences unrelated to the 
condition of interest. Th erefore, an overestimation of the 
number of missed working time because of psoriasis can-
not be ruled out. However, our qualitative fi nding that 
HRQL unlike clinical severity of psoriasis is related to 
Covariate Odds 
ratio
95% confi dence
interval
p value
Impairment of HRQL
Low (DLQI <6) reference
Moderate (DLQI 6–12) 4.48 1.89–10.65 0.001
High (DLQI >12) 7.81 2.91–21.00 <0.001
Objective severity of psoriasis
Mild (mSAPASI <7) reference
Moderate to severe (mSAPASI 67) 1.05 0.51–2.14 0.895
Presence of psoriatic lesions on hands (current) 1.58 0.83–3.03 0.166
Temporal/permanent disability 12.69 1.89–84.99 0.009
Hosmer-Lemeshow 2 5.99 (p = 0.42)
a Adjusted for age, gender, annual household income and weekly working time. 
Table 3. Multi-adjusteda logistic regression 
on productivity loss because of disease-
related absences and presenteeism 
(productivity loss 67.3% vs. productivity 
loss <7.3%; n = 201)
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HRWPL would neither be infl uenced by an overrepresen-
tation of patients with more disease-related work limita-
tions nor by diff erential recall bias with respect to the rea-
son for missed working time. 
 A possible limitation of our study is the validity of the 
case defi nition. 96% of the study subjects reported that 
psoriasis was diagnosed by a physician. In another sample 
of psoriasis patients, Shikiar et al. [64] observed high con-
struct validity of self-reported data both with respect to 
each other and to clinical assessments. Participants with 
lower HRWPL were less likely to have physician-diag-
nosed psoriasis so that a selection bias would underesti-
mate the true HRWPL of psoriasis patients ( table 1 ). In 
order to be applicable for the Internet setting, we used a 
modifi ed version of the SAPASI with direct estimation of 
BSA involvement. Th e distribution in our sample of the 
mSAPASI was 9.5  8 8.9, which is almost identical to the 
distribution of the SAPASI in its validation study  [40] . 
Both WLQ and DLQI are instruments with adequate psy-
chometric properties but have not been validated in an 
Internet setting before  [26, 37] . Th e observed distribution 
of the DLQI was highly similar to the distributions ob-
served in other settings  [37] . Th e accuracy of self-report-
ed absence days has been established by Revicki et al.  [65] . 
Overall, the quality of the collected data is considered 
high, particularly with regard to internal validity. 
 Th e mean WLQ output demands score we observed for 
psoriasis was similar to other chronic conditions including 
rheumatoid arthritis, osteoarthritis and dysthymia  [28, 29, 
31] . Both productivity loss due to health-related absentee-
ism and to presenteeism was about twice as high in patients 
with major depression compared to our sample  [30] . 
 Th e reader should not direct his attention primarily on 
the exact dollar cost of HRWPL in psoriasis patients. Th e 
message of the presented analysis is rather that the eco-
nomic impact of HRWPL clearly exceeds the direct treat-
ment-related costs  [16] . With the formula we applied the 
annual costs of presenteeism and absenteeism are only ap-
proximations. Th e distributions of both presenteeism and 
absenteeism were positively skewed, but averages were 
used in the formula so that the true cost might be under-
estimated. On the other hand, because health-related 
rather than psoriasis-related productivity loss was as-
sessed, comorbidity probably accounts for an overestima-
tion of HRWPL solely attributable to psoriasis. Th e calcu-
lated cost assumes both generalizability of our productiv-
ity loss data and applicability of the average annual income 
data on the average employed psoriasis patient. Problems 
with these assumptions could have possibly biased our 
estimation in both directions. We further assumed that 
the unemployment rate in our study sample was general-
izable to all psoriasis patients in the USA. However, un-
employment was about 3 times more likely in our sample 
than in the US general population (16.3 vs. 5.5%)  [66] . 
Th is fi nding suggests an additional economic burden of 
psoriasis due to increased unemployment, which is not 
included in our calculation. 
 Our fi ndings suggest that HRQL is an independent 
predictor of HRWPL. Th e weak crude association be-
tween HRWPL and clinical disease severity (mSAPASI) is 
probably confounded by HRQL impairment. Controlling 
for HRQL even involvement of the hands, one of the most 
obvious predictors of HRWPL, was only weakly associ-
ated with work productivity. Th is highlights that – at least 
from a societal health-economic perspective – strategies 
need to primarily focus on the patients’ subjective well-
being rather than on objective clinical signs. 
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